Drug Trial Radar · NCT07241520
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,096
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Jun 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Shanghai Hutchison Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Beijing Tiantan Hospital
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
Conditions
- Acute Ischemic Stroke
Interventions
SHPL-49 InjectionDrug
2 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7 days.
Placebo InjectionDrug
2 ampoules of Placebo Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute intravenous infusion and applied twice daily for 7days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (mRS), with scores of 0-1 at Day 90Time frame: 90±7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linfen Central Hospital
Linfen, Shanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.